FDA批准扩大HYQVIA适应症:用于2至16岁患有原发性免疫缺陷的儿童患者 武田公司于2023年4月11日宣布美国食品药品监督管理局(FDA)已经批准了HyQvia(人正常免疫球蛋白(10%),重组人透明质酸酶)的一项补充生物制剂许可申请(sBLA),扩大至2至16岁患有原发性免疫缺陷(PI)的儿童。HYQVIA最初于2014年获得批准,用于治疗成人...
已知的对人白蛋白的全身超敏反应(在透明质酸酶溶液中) 参考来源:Takeda Receives FDA Approval to Expand the Use ofHyQvia® to Treat Primary Immunodeficiency in Children 【温馨提示】 如需要更多HyQvia资讯,欢迎与致泰药业联络查询。香港致泰药业是经香港政府卫生署注册的药品批发商,专注于全球新特药品进出口业务。
FDA approval history Drug class: immune globulins En español Related treatment guides Chronic Inflammatory Demyelinating Polyradiculoneuropathy Primary Immunodeficiency SyndromeFurther information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal ...
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345. ...